Marinomed Biotech AG Achieves Restructuring Milestone

Marinomed Biotech AG has announced the fulfillment of all necessary conditions for completing its restructuring proceedings. Funds to cover the cash quota and legal costs have been secured, with a standstill agreement reached with the European Investment Bank (EIB), allowing Marinomed until April 2025 to receive payments from the sale of its Carragelose business.

The restructuring plan approved by creditors includes a 30% quota payable over two years, with a potential increase depending on Carragelose business performance. A convertible bond agreement with the EIB for kEUR 424 further supports Marinomed’s strategy.

Unither Pharmaceuticals' acquisition of the Carragelose business aims to finance Marinomed's operations and projects. This transaction, pending shareholder approval, is key to the company's sustainable future.